What common drugs have dangerous interactions with ivermectin?

1. Major groups implicated: blood thinners, CYP3A4/P‑gp substrates, and sedatives

Public drug interaction listings single out warfarin (a commonly used oral anticoagulant) and many CYP3A4/P‑gp substrate drugs — a biochemical class that includes some macrolide antibiotics, HIV protease inhibitors, certain statins, calcium‑channel blockers and benzodiazepines — as principal concerns when co‑administered with ivermectin because they can raise ivermectin exposure or potentiate adverse effects ^{[1] [2] [5]}.

2. Warfarin and bleeding risk — a distinct, actionable danger

Regulatory and clinical summaries explicitly warn that ivermectin can interact with warfarin and other anticoagulants with possible alteration of anticoagulant effect and bleeding risk, and the FDA and prescribing references advise caution and monitoring of anticoagulation parameters when these drugs are combined ^{[5] [6]}.

3. CYP3A4 and P‑glycoprotein interactions: why some antibiotics, antivirals and statins matter

Mechanistic reviews and case reports link co‑use of ivermectin with drugs metabolized by CYP3A4 or transported by P‑gp — such as macrolides (e.g., azithromycin), HIV protease inhibitors, certain statins and calcium‑channel blockers — to increased ivermectin brain penetration or blood levels and to rare but serious neurological adverse events (dizziness, ataxia, encephalopathy) documented in post‑marketing case series ^{[2] [7] [8]}.

4. Antibiotic pairings and specific examples: azithromycin and albendazole

Pharmacokinetic studies and focused reviews report that co‑administration of ivermectin with azithromycin or albendazole can increase ivermectin concentrations and thereby elevate the risk of CNS effects, making those antibiotic/anthelmintic combinations notable examples of clinically relevant interactions to avoid or monitor closely ^{[7] [8]}.

5. Sedation, alcohol and CNS depression — everyday substances that raise risk

Routine exposures matter: alcohol can augment ivermectin’s side‑effects such as dizziness and sleepiness and may increase ivermectin blood levels or additive toxicity, and clinicians routinely counsel patients to avoid alcohol during therapy ^{[9] [5] [3]}.

6. How common and how severe: many potential interactions but serious events are relatively rare

Databases list over 100 possible ivermectin interactions, and authoritative reviews emphasize that although serious neurological events have been reported, they appear uncommon relative to ivermectin’s long history of use; nevertheless, identifiable risk factors (co‑administered CYP3A4/P‑gp drugs, blood‑brain‑barrier compromise) and case reports justify careful screening and monitoring ^{[1] [2] [8]}.

7. Practical guidance and limits of the reporting

Authoritative sources (drug interaction checkers, FDA communication, clinical monographs) converge on a single practical rule: disclose all medications, avoid unnecessary combinations (especially warfarin, strong CYP3A4/P‑gp inhibitors, sedatives and alcohol), and monitor clinically and with laboratory testing where indicated; sources also note that labeling does not list every possible interaction and that some risks stem from case reports rather than large trials, so clinical judgment is required ^{[4] [6] [1]}. Reporting reviewed here is limited to published interaction lists, mechanistic reviews and case series; it does not replace individualized medical advice or capture interactions that may be identified later ^[8].